Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1989 May;27(5):932–937. doi: 10.1128/jcm.27.5.932-937.1989

Investigation of atypical western blot (immunoblot) reactivity involving core proteins of human immunodeficiency virus type.

S L Josephson 1, N S Swack 1, M T Ramirez 1, W J Hausler Jr 1
PMCID: PMC267457  PMID: 2501354

Abstract

Serum specimens which originally exhibited a narrow (indeterminate) 24-kilodalton core protein (p24) or p24/p55 pattern of reactivity with human immunodeficiency virus (HIV) in the Western blot (immunoblot) test were studied to gather information on antibody specificity. A total of 12 specimens were initially reevaluated with an indirect immunofluorescence assay (IFA), three enzyme-linked immunosorbent assays (ELISAs), and Western blot analyses. Five of the specimens were IFA positive and contained anti-gp160/gp120 antibodies which were observed only when an HIV Western blot antigen rich in gp160 and gp120 was used. The remaining seven serum specimens were nonreactive by IFA and showed variable reactivity in HIV antibody ELISAs. The specimens did not cross-react with core antigens for human T-cell leukemia virus types 1 and 2 or contain detectable levels of HIV p24 antigen. The p24/p55 reactivity of six of the seven indeterminate specimens could be reduced or eliminated by preincubating the specimens with disrupted, HIV-infected H9 cells but not with uninfected H9 cells. The six specimens also exhibited discernible reactivity with recombinant HIV p24 antigen. When an additional 23 indeterminate specimens were assayed, all of the serum specimens were nonreactive by IFA while 65% (15 of 23) showed various degrees of reactivity with the recombinant p24 protein. There was no indication that any of the HIV core antibody reactivity was caused by HIV infection. Indeterminate results for five patients with specific p24 reactivity, who were retested after a period of weeks or months, remained indeterminate for HIV antibody with no significant change in ELISA or Western blot reactivity.

Full text

PDF
932

Images in this article

934Image
on p.934
934Image
on p.934
935Image
on p.935
935Image
on p.935
935Image
on p.935
935Image
on p.935

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burke D. S., Redfield R. R., Putman P., Alexander S. S. Variations in Western blot banding patterns of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. J Clin Microbiol. 1987 Jan;25(1):81–84. doi: 10.1128/jcm.25.1.81-84.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Casey J. M., Kim Y., Andersen P. R., Watson K. F., Fox J. L., Devare S. G. Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24. J Virol. 1985 Aug;55(2):417–423. doi: 10.1128/jvi.55.2.417-423.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Couroucé A. M., Muller J. Y., Richard D. False-positive Western blot reactions to human immunodeficiency virus in blood donors. Lancet. 1986 Oct 18;2(8512):921–922. doi: 10.1016/s0140-6736(86)90443-5. [DOI] [PubMed] [Google Scholar]
  4. Gallo D., Diggs J. L., Shell G. R., Dailey P. J., Hoffman M. N., Riggs J. L. Comparison of detection of antibody to the acquired immune deficiency syndrome virus by enzyme immunoassay, immunofluorescence, and Western blot methods. J Clin Microbiol. 1986 Jun;23(6):1049–1051. doi: 10.1128/jcm.23.6.1049-1051.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Karpas A., Malik K., Lida J. Studies of human retroviruses in relation to adult T-cell leukaemia, acquired immune deficiency syndrome, and multiple sclerosis. Arch Virol. 1987;95(3-4):237–249. doi: 10.1007/BF01310783. [DOI] [PubMed] [Google Scholar]
  6. Kitchen L., Malone G., Orgad S., Barin F., Zaizov R., Ramot B., Gazit E., Kreiss J., Leal M., Wichmann I. Viral envelope protein of HTLV-III is the major target antigen for antibodies in hemophiliac patients. J Infect Dis. 1986 Apr;153(4):788–790. doi: 10.1093/infdis/153.4.788. [DOI] [PubMed] [Google Scholar]
  7. Kleinman S., Fitzpatrick L., Secord K., Wilke D. Follow-up testing and notification of anti-HIV Western blot atypical (indeterminant) donors. Transfusion. 1988 May-Jun;28(3):280–282. doi: 10.1046/j.1537-2995.1988.28388219161.x. [DOI] [PubMed] [Google Scholar]
  8. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  9. Lelie P. N., van der Poel C. L., Reesink H. W. Interpretation of isolated HIV anti-p24 reactivity in Western blot analysis. Lancet. 1987 Mar 14;1(8533):632–632. doi: 10.1016/s0140-6736(87)90274-1. [DOI] [PubMed] [Google Scholar]
  10. Manzari V., Gismondi A., Barillari G., Morrone S., Modesti A., Albonici L., De Marchis L., Fazio V., Gradilone A., Zani M. HTLV-V: a new human retrovirus isolated in a Tac-negative T cell lymphoma/leukemia. Science. 1987 Dec 11;238(4833):1581–1583. doi: 10.1126/science.2825353. [DOI] [PubMed] [Google Scholar]
  11. Ranki A., Valle S. L., Krohn M., Antonen J., Allain J. P., Leuther M., Franchini G., Krohn K. Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. Lancet. 1987 Sep 12;2(8559):589–593. doi: 10.1016/s0140-6736(87)92985-0. [DOI] [PubMed] [Google Scholar]
  12. Saah A. J., Farzadegan H., Fox R., Nishanian P., Rinaldo C. R., Jr, Phair J. P., Fahey J. L., Lee T. H., Polk B. F. Detection of early antibodies in human immunodeficiency virus infection by enzyme-linked immunosorbent assay, Western blot, and radioimmunoprecipitation. J Clin Microbiol. 1987 Sep;25(9):1605–1610. doi: 10.1128/jcm.25.9.1605-1610.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sarngadharan M. G., Bruch L., Popovic M., Gallo R. C. Immunological properties of the Gag protein p24 of the acquired immunodeficiency syndrome retrovirus (human T-cell leukemia virus type III). Proc Natl Acad Sci U S A. 1985 May;82(10):3481–3484. doi: 10.1073/pnas.82.10.3481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schüpbach J., Haller O., Vogt M., Lüthy R., Joller H., Oelz O., Popovic M., Sarngadharan M. G., Gallo R. C. Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N Engl J Med. 1985 Jan 31;312(5):265–270. doi: 10.1056/NEJM198501313120502. [DOI] [PubMed] [Google Scholar]
  15. Weber J. N., Clapham P. R., Weiss R. A., Parker D., Roberts C., Duncan J., Weller I., Carne C., Tedder R. S., Pinching A. J. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet. 1987 Jan 17;1(8525):119–122. doi: 10.1016/s0140-6736(87)91964-7. [DOI] [PubMed] [Google Scholar]
  16. van der Poel C. L., Reesink H. W., Tersmette T., Lelie P. N., Huisman H., Miedema F. Blood donations reactive for HIV in Western blot, but non-infective in culture and recipients of blood. Lancet. 1986 Sep 27;2(8509):752–753. doi: 10.1016/s0140-6736(86)90273-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES